Were the ROIV share sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5-1 plan adopted on March 28, 2025.

ROIV Form 4: Officer sells 851,383 shares via 10b5-1 plan

Roivant Sciences (ROIV) officer Eric Venker, President & Immunovant CEO, reported option exercises and open‑market sales.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Roivant Sciences (ROIV) officer Eric Venker, President & Immunovant CEO, reported option exercises and open‑market sales. On 10/15–10/17/2025, he exercised 851,383 stock options at $15.85 and sold 851,383 common shares at weighted average prices of $16.93, $17.05, and $17.06, respectively. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following these trades, he beneficially owns 1,504,959 common shares directly.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 9 txns

Insider Venker Eric

Role President & Immunovant CEO

Sold 851,383 shs ($14.47M)

Approx. gross sale proceeds $14.47M

Approx. exercise cost $13.49M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	118,418	$0.00	$0.00
Exercise	Common Shares	118,418	$15.85	$1.88M
Sale	Common Shares	118,418	$17.06	$2.02M
Exercise	Stock Option (Right to Buy)	318,282	$0.00	$0.00
Exercise	Common Shares	318,282	$15.85	$5.04M
Sale	Common Shares	318,282	$17.05	$5.43M
Exercise	Stock Option (Right to Buy)	414,683	$0.00	$0.00
Exercise	Common Shares	414,683	$15.85	$6.57M
Sale	Common Shares	414,683	$16.93	$7.02M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Shares — 1,504,959 shares (Direct)

Footnotes (2)

F1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
F2. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ROIV’s officer report on Form 4?

He reported exercising 851,383 options at $15.85 and selling 851,383 common shares at weighted average prices on 10/15–10/17/2025.

What were the sale prices disclosed for ROIV shares?

Weighted average prices were $16.93 on 10/15/2025, $17.05 on 10/16/2025, and $17.06 on 10/17/2025.

How many ROIV shares does the reporting person now own?

The filing shows 1,504,959 common shares beneficially owned directly after the reported transactions.

What positions does the reporting person hold at Roivant?

He is an officer, listed as President & Immunovant CEO.

What options were exercised in the ROIV Form 4?

Stock options with a $15.85 exercise price, fully vested from an award with a vesting commencement date of December 27, 2019.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 10/17/2025 - 09:00 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Venker Eric

(Last)

(First)

(Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON

SW1H 0DB

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & Immunovant CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	10/15/2025		M		414,683	A	$15.85	1,919,642	D
Common Shares	10/15/2025		S		414,683	D	$16.93⁽¹⁾	1,504,959	D
Common Shares	10/16/2025		M		318,282	A	$15.85	1,823,241	D
Common Shares	10/16/2025		S		318,282	D	$17.05⁽¹⁾	1,504,959	D
Common Shares	10/17/2025		M		118,418	A	$15.85	1,623,377	D
Common Shares	10/17/2025		S		118,418	D	$17.06⁽¹⁾	1,504,959	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$15.85	10/15/2025		M			414,683	⁽²⁾	03/31/2026	Common Stock	414,683	$0	436,700	D
Stock Option (Right to Buy)	$15.85	10/16/2025		M			318,282	⁽²⁾	03/31/2026	Common Stock	318,282	$0	118,418	D
Stock Option (Right to Buy)	$15.85	10/17/2025		M			118,418	⁽²⁾	03/31/2026	Common Stock	118,418	$0	0	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

2. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

	By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR